A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Trial details
- Registry ID
- NCT06682806
- Drugs studied
- PRT3789, pembrolizumab
TrialRedline tracks 1 clinical trial sponsored by Prelude Therapeutics Incorporated: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06682806 | PRT3789, pembrolizumab | Terminated | 2026-01-23Actual |
Names as written in the registry records.
NCT06682806 · Prelude Therapeutics Incorporated
Before: 7 participants (actual). After: 6 participants (actual).
Before: Estimated. After: Actual.
Before: Aug 2027. After: 23 Jan 2026.
Before: Active not recruiting. After: Terminated.